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doi:10.1016/j.gmbhs.2012.04.012Abstract The detection of circulating tumor cells (CTCs) is believed to be a potential method
for the early detection of cancer. The aim of this study was to employ a membrane array to
develop a panel of mRNA markers for the detection of CTCs in breast cancer patients. Twenty
genes with highly differentiated expression levels were selected from microarray studies. The
subsequent validation analysis of 30 pairs of breast tissue samples showed that 19 genes
demonstrated two-fold overexpression in cancer tissues in comparison with those in normal
tissues in 80% of the paired samples. Furthermore, a membrane array experiment was con-
ducted on blood samples from 64 normal controls and 87 breast cancer patients, and the
predictive power of each gene was evaluated by analyzing the gene expression level using
receiver-operating curves (ROC). Among the 20 genes selected, eight genes that demonstrated
the largest areas under the curve (AUC) > 0.8 were selected as diagnostic markers. According
to the ROC analysis, when setting the cut-off point of five positive genes, the genetic array of
the eight markers was recognized as positive with sensitivity and specificity values of 90% and
89%, respectively. These results suggest that this mRNA marker array could be useful for de-
tecting CTCs in breast cancer patients.
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mRNA markers for CTCs detecting in breast cancer patients 35Introduction QIAamp RNA Blood Mini Kit (QIAGEN Inc., Valencia, CA, USA),The incidence and the death rate of breast cancer are at the
first and fourth stage of all types of cancer in Taiwanese
women, respectively,1 showing that breast cancer is a serious
threat to the health of women. Early detection is one of the
most effective means of reducing cancer mortality. Through
appropriate treatment, the 5-year average survival rate of
breast cancer can reach up to 88% if detected during stage 1
and 93% when detected during stage 0.2 Therefore, break-
through diagnosticmethods that can detect breast cancer are
expected to decrease the death rate of breast cancer.
The most convenient, side effect-free, and acceptable
method for the initial diagnosis and detection of breast
cancer on postoperative follow-up examination is the use of
peripheral blood samples. However, the detection sensi-
tivity and specificity of traditional serum tumor markers,
such as carcinoembryonic antigen (CEA) and carbohydrate
antigen 15-3 and 27.29 (CA15-3 and CA27.29, respectively),
are low and should be used along with physical examination
and diagnostic imaging tests. In addition, tumor markers
are heterogeneously expressed in breast cancer and the
detection of a single marker may result in unsatisfactory
specificity. The use of mRNA panels has been suggested as
a way to potentially improve accuracy and reliability.3
Therefore, the aim of this study is to detect circulating
tumor cells (CTCs) in breast cancer patients using a multi-
marker assay that was previously developed in our labora-
tory.4 Hopefully, this multimarker assay will become an
effective tool for the detection of breast cancer on the
initial diagnosis and follow-up examinations.
Materials and methods
Specimen collection
Thirty paired tumor tissues and 87 peripheral blood samples
were collected from patients with breast cancer at
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
In addition, peripheral blood samples were obtained from
64 healthy volunteers to serve as controls. All specimen
donors were females, and the age distributions of the
volunteers and patients were similar.
Microarray and bioinformatics analysis
Three pairs of normal and breast cancer tissues of different
cell types were selected for two-color microarray experi-
ments using the Agilent Human 1A (V2) Oligo chip (Agilent
Technologies Inc., Santa Clara, CA, USA) according to the
manufacturer’s instructions. The data from the microarray
were analyzed using GeneSpring software (Agilent Tech-
nologies). Twenty genes were selected because their
expression levels were significantly higher in breast cancer
tissue than normal tissue (p < 0.05).
Total RNA extraction and cDNA synthesis
Total RNA was isolated from the tissue and blood samples
from the patients and controls using the RNeasy Mini Kit andrespectively. First-strand cDNA was synthesized from the
total RNA using the Transcriptor First Strand cDNA Synthesis
Kit (Roche Diagnostics Ltd., Mannheim, Germany).
Oligonucleotide membrane array
The oligonucleotide probe sequences of the 20 candidate
genes are shown in Table 1. The procedure of the
membrane array was performed according to our previously
published methods.4 The density of each gene was divided
by b-actin to serve as an internal control. For tissue sample
validation, the expression ratio of each gene was calculated
by quantifyingthe spot densities of each tumor tissue and
dividing by the results of the paired normal tissue sections.
A gene was considered overexpressed when the ratio was
>2.0. For the blood sample tests, each gene was consid-
ered positive according to the cut-off values selected from
Receiver-operating characteristic (ROC) curves.
Statistical analysis
All data were analyzed using the Statistical Package for the
Social Sciences software (version 12.0; SPSS Inc., Chicago,
IL, USA). Receiver-operating characteristic (ROC) curves
were constructed by plotting all possible sensitivity/speci-
ficity pairs for each gene and the results of the membrane
array analysis, resulting in continuously varying cut-off
values over the entire range of results obtained.
Results
The tissue and blood samples were used for gene expres-
sion confirmation using the membrane array. Mean spot
densities that consistently varied by a factor of >2.0 were
considered positive. The positivity rate of each gene
analyzed in the 30 pairs of normal and breast cancer
tissues are shown in Table 2. Nineteen genes demon-
strated >2.0-fold overexpression in the tumor tissues in
comparison with the genes in normal tissues in 80% of the
paired samples. Next, the gene expression levels in the
peripheral blood samples from 87 breast cancer patients
at every stage and 64 normal volunteers were analyzed
using the membrane array. The densities were calculated
by ROC analysis, and the total area-under-the-curve (AUC)
value was calculated for each gene. According to the AUC
value of each gene, eight genes were selected as diag-
nostic markers because their AUC values were >0.8. The
cut-off-value of each gene was considered positive if it
was in accordance to the optimal sensitivity and speci-
ficity. Furthermore, eight genes were combined for the
ROC analysis, and the cut-off point for positivity was set to
5.0. At this cut-off point, the sensitivity and specificity
values of the eight markers for detecting CTCs were 90%
and 89%, respectively (Fig. 1).
Discussion and conclusion
Among the 20 genes selected from the microarray anal-
ysis, most genes have been reported as being correlated
Table 1 Nucleotide sequences of 20 candidate probes.
Gene Sequence
COL10A1 5’-AGAGGAGTGGACATACTCAGAGGAGTATAGGCCATTTGACTCGGCATTGG-3’
CDKN3 5’-GGAGACAAGCAGCTACAAGACAAGATCTCCCAAGTCCTCCATAGCAGTGT-3’
FAM83D 5’-TCAGTAAAGAGTGTTCTCCTTGACAGCATAGCCAGCATGTGGTTGAGCCG-3’
S100P 5’-CCATTGGCGTCCAGGTCCTTGAGCAATTTATCCACGGCATCCTTGTCTTT-3’
HMMR 5’-CAGCGAAAGGGTTCAGAATGAGGTGATAAAGGTGAGCATTAGGGAGGAGG-3’
CEP55 5’-TGATGAACCATGTCAGGGAGGTATCACTGCCAAGAGAAATGCACAGCAGC-3’
SPAG5 5’-GCAAGCACAAGGCCTGGTTCAGCTTCTCTATGTCTGCTTCTTTTGCCTTC-3’
SLC9A3R1 5’-AGCGGCAGTTCTGCAGTCAGAGTTCTTTGATCAGCCCTGGACCCATTTAT-3’
PTTG1 5’-AAGGAGACTGCAACAGATTGGATTCCCATGGTGGAGAGGGCATCTTCACA-3’
CKS2 5’-CTCGTAGTGTTCGTCGAAGTACTTGTCCGAGTAGTAGATCTGCTTGTGGG-3’
MAD2L1 5’-GAAGGCGGACTTCCTCAGAATTGGTAATAAACTGTGGTCCCGACTCTTCC-3’
HSPC121 5’-CAGAGTGTAACGAAGCCATGTGAGCACCTTCCAATCCATGTCAATGCACG-3’
TOP2A 5’-AAATTGGTTTCTCTCTTTGGGAGATTCAGACTCAGAGGCAGCCAGAGGGG-3’
BIRC5 5’-CCACCTGAAGTTCACCCCGTTTCCCCAATGACTTAGAATGGCTTTGTGCT-3’
UBE2C 5’-TCAGGGAAGGCAGAAATCCCTTTATCGCCAGACATCATGAGGGTCATCAG-3’
CDCA8 5’-GGGACCACTGGACCATGGATAGCTTAGAGACAGTTATTCTGTGGCCAATG-3’
CCNB1 5’-CCGACCCAGTAGGTATTTTGGTCTGACTGCTTGCTCTTCCTCAAGTTGTC-3’
TK1 5’-TTGGCATACTTGATCACCAGGCACTTGTACTGAGCAATCTGGAAGCGACG-3’
TPX2 5’-GAGCACCTCTTCTGTCAGTCTCCAAGCAGAAAGGTTCAATCTGGGTCACA-3’
FOXM1 5’-CACAAGGTCCCAGCAGTGGCTAGGGTGTGACTGCTACTTTTGCATAATCA-3’
36 H.-C. Hung et al.with breast tumor cells by several studies.5,6 Clinical
validation using a combination of multiple markers was
also performed in the present study. Compared with other
multimarker assays,7,8 the detected sensitivity and spec-
ificity values of our membrane array were effectively
elevated to approximately 90%. This membrane array is
a highly sensitive and reliable method for detecting CTCsTable 2 The positivity rate of each gene in the 30 pairs of
breast cancer tissue.
Gene Positivity rate (no.)
COL10A1 66.7% (20/30)
CDKN3 83.3% (25/30)
FAM83D 90.0% (27/30)
S100P 83.3% (25/30)
HMMR 80.0% (24/30)
CEP55 86.7% (26/30)
SPAG5 86.7% (26/30)
SLC9A3R1 90.0% (27/30)
PTTG1 83.3% (25/30)
CKS2 86.7% (26/30)
MAD2L1 90.0% (27/30)
HSPC121 80.0% (24/30)
TOP2A 86.7% (26/30)
BIRC5 80.0% (24/30)
UBE2C 83.3% (25/30)
CDCA8 90.0% (27/30)
CCNB1 86.7% (26/30)
TK1 83.3% (25/30)
TPX2 83.3% (25/30)
FOXM1 80.0% (24/30)in peripheral blood samples from breast cancer patients.
In addition, it might find useful applications in post-
operative follow-up examinations because of its con-
venience. In order to improve its early diagnostic or
prognostic potential of detecting breast cancer, correla-
tions between the gene expression patters of the0.0 0.2 0.4 0.6 0.8 1.0
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Figure 1 Result of the ROC analysis after combining the 8
selected genes. When the cut-off value was set to 5 to indicate
the membrane array as positive, the detected sensitivity and
specificity values of the 8 markers for circulating cancer cells
were 90% and 89%, respectively.
mRNA markers for CTCs detecting in breast cancer patients 37membrane array and the clinical/pathological phenotypes
of breast cancer patients need to be further studied.
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